SWOG clinical trial number
SWOG-8507

Maintenance versus no Maintenance BCG Immunotherapy of Superficial Bladder Cancer

Closed
Phase
III
Published
Abbreviated Title
Maintenance versus no Maintenance BCG Immunotherapy of Superficial Bladder Cancer
Activated
12/20/1985
Closed
12/15/1988

Research committees

Genitourinary Cancer

Treatment

BCG

Publication Information Expand/Collapse

2019

Mechanisms and Funding Opportunities in Genitourinary Cancer Clinical Research

C Ryan Urologic Oncology: Seminars and Original Investigations, May;37(5):318-323; Jul 31 [Epub ahead of print]

PMid: PMID30072304

2017

Association between body mass index and cancer survival in a pooled analysis of 22 clinical trials

H Greenlee;J Unger;M Leblanc;S Ramsey;D Hershman Cancer Epidemiology Biomarkers & Prevention 2017 Jan;26(1):21-29; 2016 Dec 16. [Epub ahead of print]

PMid: PMID27986655 | PMC number: PMC5370550

2016

Summary and recommendations from the National Cancer Institute's Clinical Trials planning meeting on novel therapeutics for non-muscle invasive bladder cancer

SP Lerner;DF Bajorin;CP Dinney;JA Efstathiou;S Groshen;NM Hahn;D Hansel;D Kwiatkowski;M O'Donnell;J Rosenberg;R Svatek;JS Abrams;H Al-Ahmadie;AB Apolo;J Bellmunt;M Callahan;EK Cha;C Drake;J Jarow;A Kamat;W Kim;M Knowles;B Mann;L Marchionni;D McConkey;L McShane;N Ramirez;A Sharabi;AH Sharpe;D Solit;CM Tangen;AT Amiri;E Van Allen;PJ West;JA Witjes;D Quale Bladder Cancer Apr 27;2(2):165-202

PMid: PMID27376138 | PMC number: PMC4927845

2014

Association between BMI at treatment initiation and cancer survival across multiple SWOG trials

H Greenlee;J Unger;M Leblanc;D Hershman AACR Research International Conference on Frontiers on Cancer Research Prevention (Sept 28-Oct 1, 2014, New Orleans, LA; poster

2009

Failure to achieve a complete response to induction BCG therapy is associated with increased risk of progression and death in patients with high risk non-muscle invasive bladder cancer [PMC2695968; PMID18367117]

SP Lerner;CM Tangen;H Sucharew;DP Wood;ED Crawford Urologic Oncology 27(2):155-159

2008

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

2007

Patterns of recurrence and outcomes following induction bacillus calmette-guerin for high risk Ta, T1 bladder cancer [PMID17437798]

SP Lerner;CM Tangen;H Sucharew;D Wood;ED Crawford Journal of Urology 177:1727-1731

2004

Timing of recurrence and outcomes following induction BCG for high risk Ta, T1 bladder cancer - a Southwest Oncology Group Trial

SP Lerner;C Tangen;H Sucharew;D Wood;ED Crawford Journal of Urology 171(Suppl 4):72(#273)

2000

Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study

DL Lamm;BA Blumenstein;JD Crissman;JE Montie;JE Gottesman;BA Lowe;MF Sarosdy;RD Bohl;HB Grossman;TM Beck;JT Leimert;ED Crawford Journal of Urology 163:124-1129

1999

Maintenance BCG immunotherapy: Evidence of additional protection against cancer. A Southwest Oncology Group study.

DL Lamm;JD Crissman;JE Montie;JE Gottesman;BA Lowe;MF Sarosdy;RD Bohl;HB Grossman;TM Beck;JT Leimert;ED Crawford;U Kosecka;RC Wittes Proc of the American Urological Association :#1464

1997

Significant long-term patient benefit with BCG maintenance therapy: A Southwest Oncology Group study.

DL Lamm;B Blumenstein;M Sarosdy;HB Grossman;ED Crawford Journal of Urology 157(4)Suppl:213(#831)

1992

Maintenance BCG immunotherapy of superficial bladder cancer: A randomized prospective Southwest Oncology Group study.

DL Lamm;ED Crawford;B Blumenstein;MF Sarosdy;HB Grossman;RD Bohl;B Lowe;TD Moon;WL Weems;TM Beck;J Montie;JA Smith;J Crissman;CA Coltman Jr ASCO 11:203(#627)

Other Clinical Trials

SWOG Clinical Trial Number
S1806

Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.

Research Committee(s)
Genitourinary Cancer
Activated
04/19/2019
Accrual
2%
Open
Phase
III
SWOG Clinical Trial Number
S1802
SWOG Clinical Trial Number
CTSU/EA8153